Author

C. Mackenzie-Kludas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

D. A. Elliott· 2 shared D. Abu-Bonsrah· 2 shared K. Karavendzas· 2 shared K. Subbarao· 2 shared S. J. Humphrey· 2 shared A. C. Hurt· 1 shared A. Salavaty· 1 shared A. Suhrbier· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

D. A. Elliott

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A new concept in antiviral drug design yields a potent influenza inhibitor

C. Mackenzie-Kludas, W.-Y. Wu, B. Jin, J. L. McKimm-Breschkin, E. L. Seah, P. Jones, E. Fairmaid, C. M. K. Tai, D. Y. Oh, P. Jenkins, A. C. Hurt, L. E. Brown

This paper introduces a new antiviral drug design approach that alters the virion surface microenvironment to block influenza virus entry, showing potent in vitro and in vivo activity.

bioRxiv · Nov 8, 2022 · PreprintMicrobiology

Parallel use of pluripotent human stem cell lung and heart models provide new insights for treatment of SARS-CoV-2

R. Rudraraju, M. J. Gartner, J. A. Neil, E. S. Stout, J. Chen, E. J. Needham, M. See, C. Mackenzie-Kludas, L. Y. Yang, M. Wang, H. Pointer, K. Karavendzas, D. Abu-Bonsrah, D. Drew, Y. B. Y. Sun, , K. Subbarao

The paper uses human pluripotent stem cell-derived lung and heart models to identify antiviral compounds with distinct profiles, highlighting the need for multi-organ testing in SARS-CoV-2 treatment.

bioRxiv · Sep 20, 2022 · PreprintMicrobiology

Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical)

R. J. Mills, S. J. Humphrey, P. R. Fortuna, M. Lor, S. R. Foster, G. A. Quaife-Ryan, R. L. Johnston, T. Dumenil, C. Bishop, R. Ruraraju, D. J. Rawle, T. Le, W. Zhao, L. Lee, C. Mackenzie-Kludas, , E

The paper identifies BET inhibitors as potential cardio-protective drugs that block inflammation-induced cardiac dysfunction and SARS-CoV-2 infection in pre-clinical models.

bioRxiv · Aug 23, 2020 · PreprintCell Biology